S
ince its description in 1978 by Parks et al, 1 the surgical treatment of choice for chronic ulcerative colitis (CUC) is restorative proctocolectomy and ileal pouch-anal anastomosis (IPAA) due to its ability to remove at risk colon and rectum while maintaining intestinal continuity with excellent long-term pouch function and quality of life. In fact, up to 98% of patients report they would undergo the operation again. 2 Despite these results, up to 50% of patients will experience at least one episode of pouchitis, the most common postoperative complication of the pouch after open IPAA. 3, 4 Pouchitis is a poorly understood inflammatory disorder that presents with abdominal cramping, pelvic discomfort, increased stool frequency, fecal urgency, and incontinence. 4, 5 Although there are no universally accepted diagnostic criteria for pouchitis, clinicians base their assessment on clinical, endoscopic, and histologic features. The endoscopic appearance of pouchitis includes mucosal friability, granularity, edema, loss of vascular pattern, superficial ulceration, and hemorrhage. 5, 6 Histologic confirmation of acute inflammation in pouchitis includes the presence polymorphic nuclear leukocyte infiltration, ulceration, and crypt abscess. 5, 6 Unfortunately, the etiology of pouchitis remains unknown. However, up to 95% of patients respond to antibiotic therapy, suggesting bacteria play an important role. [7] [8] [9] Clostridium difficile is an anaerobic gram-positive sporeforming bacterium that has been increasing in incidence and severity over the past few decades. 10 Rates of C. difficile infection (CDI) are higher among patients with inflammatory bowel disease (IBD), and the presence of CDI in CUC patients results in significant ulcerative colitis (UC) flares, prolonged hospital stays, higher rates of colectomy, and higher rates of postoperative infection. 11, 12 Single-center series have reported that up to 18% of patients with pouchitis have CDI, [12] [13] [14] and data suggest that concurrent CDI might contribute to chronic antibiotic-refractory pouchitis seen in 10% to 15% of patients. [15] [16] [17] However, few studies have investigated the effect of preoperative colonic CDI on post-IPAA pouch function and pouchitis frequency.
Given the high proportion of patients with CUC who present for elective, urgent, or emergent colectomy with concomitant CDI, we sought to determine the association of precolectomy CDI with post-IPAA pouchitis and long-term pouch function.
PATIENTS AND METHODS
After institutional board approval, a retrospective analysis of all electronic patient medical records at Mayo Clinic Rochester Data collected included baseline demographics, CUC characteristics and treatments, presence of primary sclerosing cholangitis (PSC), IPAA surgical indication and stages, 90-day postoperative complications, time to pouchitis, and frequency of pouchitis. Colectomy was defined as emergent if the patient was hospitalized and failed intravenous steroids and/or induction with infliximab, and was considered elective if the patient was admitted to the hospital the day of surgery for a scheduled colectomy. The primary endpoint was the presence of pouchitis based on clinical, endoscopic, and histologic assessment by a colorectal surgeon or gastroenterologist within 5 years of surgery. The secondary endpoint was 90-day post-IPAA morbidity including: (1) postoperative surgical site infection, hemorrhage, anastomotic leak, and fistula formation; (2) CDI of the pouch; (3) antibiotic response to pouchitis; (4) antibiotic-resistant pouchitis requiring escalation of therapy to steroids, immunomodulators, or biologic therapy; and (5) medically refractory pouchitis requiring surgical intervention (pouch excision, end-ileostomy, or fecal diversion). Acute pouchitis was diagnosed if all of the following criteria were fulfilled: (1) #3 episodes of pouchitis per year, (2) symptoms ,4 weeks, and (3) symptoms responding to a short course of antibiotics. Chronic pouchitis was defined as the presence of one or more of the following: (1) .3 episodes of pouchitis per year, (2) active symptoms lasting continuously for .4 weeks despite antibiotics, or (3) chronic antibiotic or anti-inflammatory therapy to control symptoms.
For univariate intergroup comparisons, normally distributed continuous data were expressed as mean with standard deviation and compared using the student's t test (2-tailed). Non-normally distributed continuous data were expressed as median with interquartile range and comparisons made with the Mann-Whitney U test. Categorical variables were examined with Pearson's chi-square and Fisher's exact test as appropriate based on their distribution. Time to event analysis was performed using the method of Kaplan and Meier and the logrank test was used for comparisons. Adjusted multivariable logistic regression was used to model development of pouchitis as a function of age dichotomized at 50 years, body mass index (BMI) dichotomized at 30, PSC presence, 2-versus 3-stage surgery, the presence of C difficile infection before colectomy, the use of immunomodulatory or biologic therapy before colectomy, and the urgency of surgery as defined by elective versus emergent. A P value ,0.05 was considered statistically significant for all comparisons. Missing data were handled with indicator variables, which are reported in the tables. Statistical analysis and plotting were performed with R version 3.2.4 ("Very Secure Dishes," R Foundation for Statistical Computing, Vienna, Austria; www.r-project.org).
RESULTS
Forty-eight case patients and 154 control patients were included. There were no significant differences in gender, race, ethnicity, body mass index, tobacco use, or presence of PSC between the 2 groups (Table 1) . However, patients with preoperative CDI were younger (P ¼ 0.010), more likely to have undergone colectomy for medically refractory disease (P ¼ 0.002), and had higher rates of biologic use before colectomy (P ¼ 0.046). The overall rate of pouchitis was 47.5% (n ¼ 96). There was no significant difference in the rate of pouchitis between the CDI and non-CDI cohorts with rates of 50.0% (n ¼ 24) and 46.8% (n ¼ 72) (P ¼ 0.694), respectively, or median time to pouchitis of 16.8 months (interquartile range [IQR] 7.1-31.6 mo) and 13.1 months (IQR, 6.6-29.2 mo), respectively (Fig. 1,  Table 2 ). PSC was associated with pouchitis development (odds ratio [OR] 10.59; 95% CI, 3.07-51.08; P , 0.001) on multivariate analysis (Fig. 2) . Pouchitis was not associated with baseline patient demographics, CUC characteristics, medical management before colectomy, or the number of IPAA surgical stages on univariate or multivariate analysis (Fig. 2) . For medical and surgical treatment of pouchitis, precolectomy CDI compared with no precolectomy CDI was associated with higher (P ¼ 0.042) use of anti-TNFa inhibitor at a rate of 6.3% (n ¼ 6) and 0.7% (n ¼ 1), respectively, and higher need (P ¼ 0.042) for end or diverting ileostomy at a rate of 6.3% (N ¼ 6) and 0.7% (n ¼ 1), respectively. Precolectomy CDI was not associated with pouchitis disease course (acute verses chronic), antibiotic treatment and response, or need for surgical pouch excision or end-ileostomy/ fecal diversion (Table 2) . For postoperative complications occurring within 90 days of IPAA, precolectomy CDI compared with no precolectomy CDI was associated with more frequent (P ¼ 0.018) development of an anastomotic or pouch stricture at rates of 16.7% (n ¼ 8) and 5.8% (n ¼ 9), respectively. Precolectomy CDI was not associated with other early postsurgical complications or pouch failure (Table 3) .
DISCUSSION
CDI afflicts patients with CUC more often than the general population. 18, 19 Unfortunately, the presence of CDI can not only mimic the symptoms of CUC, but can also worsen the disease severity resulting in significantly increased morbidity and mortality for patients with ulcerative colitis. 20, 21 Patients with CUC who undergo IPAA for medically refractory disease or presence of neoplasia are at risk for pouch morbidities including pouchitis, cuffitis, anastomotic stricturing, fistula, or Crohn's disease of the pouch. Pouchitis, seen in up to 50% of patients with ulcerative colitis, 3 can result in significant morbidity and the eventual need for revision or removal of the pouch altogether in 5 to 7 percent at 10 years. 22, 23 Unfortunately, the etiology of post-IPAA pouchitis remains largely unknown. Several studies have tried to retrospectively evaluate databases looking for preoperative predictors of pouchitis, 3, 24 but little data have been consistent or conclusive.
In our study, pouchitis was seen in 47.5% of patients of which 17.9% had PSC. This is a higher incidence of pouchitis than seen in previous studies, which have ranged between 24% and 46%. 3, 14, 25, 26 It is possible that this finding is related to increased severity of disease and increased number of patients with PSC treated at an IBD referral center, as both, especially PSC, has been shown to be associated with an increased incidence of pouchitis post-IPAA. Penna et al 25 studied 1097 patients with CUC who underwent IPAA; 61% of patients with PSC had a 5-year cumulative risk of pouchitis compared with 36% without PSC (P , 0.001). Abdelrazeq et al 27 studied 198 patients who underwent IPAA for CUC and found a significant increase in both the overall frequency of pouchitis (P , 0.001) and chronic pouchitis as compared to acute pouchitis (P , 0.001) among patients with PSC. Similarly, we found a significantly higher rate of pouchitis in patients with PSC (17.9%) versus those without (2.8%) on multivariable analysis (P # 0.001). Fortunately, despite the increased frequency of pouchitis among PSC patients, there does not seem to be an increased rate of pouch failure requiring pouch excision 28 or decreased quality of life. 29 Interestingly, we found that a 3-stage approach to IPAA was associated with a significantly lower rates of pouchitis (P ¼ 0.005). Although a 3-stage approach is often used in patients with increased severity of disease or on multiple immunosuppressive agents, perhaps the increased time from colectomy to pouch formation and reduced inflammation in the pelvis at time of pouch formation reduces the rate of post IPAA pouchitis. Regardless of the potential mechanism, this finding supports the ongoing use of a 3-stage IPAA for medically refractory disease on a multitude of immunosuppressive agents.
A recent study by Skowron et al 26 also reported no difference in post-IPAA pouchitis among patients with precolectomy CDI. Their study included 417 patients with CUC who underwent IPAA and found that 14.9% had CDI at any time before colectomy, among which 29% developed pouchitis compared with 31.5% in patients who did not have CDI (P ¼ 0.693). Interestingly, although we similarly found equivalent rates of pouchitis among precolectomy CDI and patients without CDI before colectomy, we did notice that the treatment of pouchitis more often required anti-TNF therapy or diversion in the precolectomy CDI group. These findings suggest that CDI may cause of more refractory pouchitis phenotype or may be that this cohort simply represents a group with increased severity of disease before colectomy.
In fact, in our study, precolectomy CDI was associated with higher CUC disease burden as suggested by increased use of biologic therapy and increased number of patients undergoing IPAA for medically refractory disease (versus presence of neoplasia). These findings corroborate with previous studies which have also suggested that CDI worsens the prognosis of CUC including escalation in medical therapy, 20 increased rate of colectomy, 20, 21 increased postoperative infectious complications, 11 increased overall postoperative complications, 21 and increased mortality. 18, 21 However, several studies, 21, 30 including ours, did not find an association between preoperative CDI and postoperative infectious complications.
The primary limitation to this study is that it is a singleinstitution retrospective review with a high degree of referred patients for complex inflammatory bowel disease. This limits the reproducibility of our findings to other institutions.
CONCLUSIONS
In patients with CUC, CDI before colectomy with IPAA does not seem to be associated with an increased risk of pouchitis or postoperative complications. However, precolectomy CDI may be associated with a higher use of anti-TNFa and surgical diversion to treat pouchitis. These findings provide reassurance about outcomes in patients with CDI before IPAA and suggest precolectomy CDI should not delay a medically indicated colectomy. At the time of colectomy, the use of a 3-stage approach may be protective and should be considered in high-risk patients.
